Randomized, Double-blind, Parallel Group, Placebo-controlled, Fixed-dose of Lu AE58054 In Patients with Mild - Moderate Alzheimer's Disease Treated with Donepazil; Study 2

StatusActive
Effective start/end date8/12/1431/12/19

Funding

  • Lundbeck Pharmaceuticals: $103,426.10

Keywords

  • Aging & Alzheimers, Biotechnology & Drug Development